Lane Aiena, MD
Family Medicine · Huntsville, TXNPI 1366855470
Payments from drug & device makers
Across 171 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$621
- Pfizer$564
- Supernus Pharmaceuticals, Inc.$201
- Lilly USA, LLC$175
- AbbVie$154
- Astellas Pharma US Inc$153
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $621 |
| Pfizer | 37 | $564 |
| Supernus Pharmaceuticals, Inc. | 1 | $201 |
| Lilly USA, LLC | 14 | $175 |
| AbbVie(2 entities) | 9 | $154 |
| Astellas Pharma US Inc | 9 | $153 |
| Gilead | 1 | $75 |
| Abbott | 4 | $71 |
| GSK | 4 | $71 |
| Edwards Lifesciences | 3 | $70 |
| Sanofi-aventis U.S. LLC | 5 | $67 |
| Sanofi Pasteur Inc. | 3 | $66 |
| Amgen | 4 | $64 |
| Dexcom, Inc. | 3 | $63 |
| Johnson & Johnson | 4 | $55 |
| Boehringer Ingelheim | 3 | $49 |
| Exact Sciences | 3 | $44 |
| Novo Nordisk | 3 | $44 |
| Boston Scientific | 2 | $35 |
| Irhythm Technologies, Inc. | 1 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Vertiflex, Inc. | 1 | $31 |
| Seqirus USA Inc | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Merck | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$201
How this compares
$3,010 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 183 | $186,523 |
| OzempicSemaglutide | 83 | $114,350 |
| MounjaroTirzepatide | 96 | $106,573 |
| JardianceEmpagliflozin | 82 | $87,219 |
| RybelsusSemaglutide | 54 | $79,806 |
| FarxigaDapagliflozin Propanediol | 50 | $70,813 |
| JanuviaSitagliptin Phosphate | 49 | $59,345 |
| XareltoRivaroxaban | 45 | $48,981 |
| TrulicityDulaglutide | 15 | $28,696 |
| Repatha SureclickEvolocumab | 25 | $24,564 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $22,047 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $18,072 |
| TradjentaLinagliptin | 26 | $17,833 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $17,016 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $16,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $564 | $201,394197 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $44 | $200,882163 claims |
| Lilly USA, LLCMounjaro, Trulicity | $175 | $135,269111 claims |
| Boehringer IngelheimJardiance, Tradjenta | $49 | $105,052108 claims |
| AstraZenecaFarxiga | $621 | $70,81350 claims |
| MerckJanuvia | $25 | $59,34549 claims |
| Johnson & JohnsonXarelto | $55 | $48,98145 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $71 | $37,49656 claims |
| AbbVieLinzess, Synthroid | $154 | $15,971104 claims |
| Astellas Pharma US IncMyrbetriq | $153 | $14,53930 claims |
| Sanofi-aventis U.S. LLCLantus | $67 | $4,31839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Huntsville
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.